Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma [0.03%]
新诊断的高级别胶质瘤周围脑组织高兴奋性的帕利哌酮剂试点试验
Steven Tobochnik,Michael S Regan,Maria K C Dorotan et al.
Steven Tobochnik et al.
Purpose: Glutamatergic neuron-glioma synaptogenesis and peritumoral hyperexcitability promote glioma growth in a positive feedback loop. The objective of this study was to evaluate the feasibility and estimated effect siz...
Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations [0.03%]
基于AR改变的前列腺癌cfDNA特征的发现
Rashad Nawfal,Razane El Hajj Chehade,Jacob E Berchuck
Rashad Nawfal
Androgen receptor (AR) alterations portend a poor prognosis in patients with advanced prostate cancer. A recent study identified a stemness signature enriched in cell-free DNA from AR-altered patients, associated with worse outcomes. These ...
Intestinal subtype as a biomarker of response to neoadjuvant immunochemotherapy in locally advanced gastric adenocarcinoma: insights from a prospective phase II trial [0.03%]
肠亚型作为局部晚期胃腺癌新辅助免疫化疗反应生物标志物的启示：一项前瞻性II期临床试验的成果
Lei Wang,Mengting Sun,Jinyang Li et al.
Lei Wang et al.
Purpose: Neoadjuvant immunochemotherapy (NAIC) markedly induces pathologic regression in locally advanced gastric adenocarcinoma (GAC). However, specific biomarkers are still lacking to effectively identify the beneficiar...
YAP regulates HER3 signaling-driven adaptive resistance to RET inhibitors in RET-aberrant cancer [0.03%]
YAP调节HER3信号驱动的RET抑制剂适应性抵抗在RET异常癌症中
Yuki Katayama,Tadaaki Yamada,Keiko Tanimura et al.
Yuki Katayama et al.
Purpose: Rearranged during transfection (RET) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients with RET-aberrant cancer are insensi...
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation [0.03%]
成人复发或难治性异柠檬酸脱氢酶-1突变急性髓系白血病患者使用Olutasidenib的FDA批准概要
Ashley C Woods,Kelly J Norsworthy,Moran Choe et al.
Ashley C Woods et al.
On December 1st, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia: Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for the treatment of adult patients with relapsed or refracto...
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma [0.03%]
肿瘤突变负荷和PD-L1与晚期尿路上皮癌派姆单抗联合或不联合化疗对比化疗的疗效相关性分析
Aude Fléchon,Rafael Morales-Barrera,Thomas Powles et al.
Aude Fléchon et al.
Purpose: The three-arm, phase III KEYNOTE-361 study did not meet its dual primary endpoints of progression-free survival (PFS) or overall survival (OS) with first-line pembrolizumab plus chemotherapy versus chemotherapy i...
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial [0.03%]
针对接受曲妥珠单抗-美坦辛（T-DM1）治疗的HER2阳性晚期乳腺癌分子影像与转录组分析：来自ZEPHIR临床试验的结果分析
Mattia Rediti,Danai Fimereli,Magdalena Mileva et al.
Mattia Rediti et al.
Purpose: The ZEPHIR clinical trial evaluated the role of [89Zr]trastuzumab-PET/CT (HER2-PET/CT) and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT ([18F]FDG-PET/CT) in predicting outcomes in patients with advanced HER2-positive b...
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes [0.03%]
奥拉帕利联合替莫唑胺治疗小细胞肺癌的I/II期研究：最终分析及中枢神经系统疗效
Catherine B Meador,Subba R Digumarthy,Beow Y Yeap et al.
Catherine B Meador et al.
Purpose: Temozolomide plus PARP inhibition has shown promise in small cell lung cancer (SCLC). We previously reported outcomes from the first 50 patients (cohort 1) of a phase I/II trial of olaparib/temozolomide in recurr...
Update on surveillance guidelines in emerging Wilms tumor predisposition syndromes [0.03%]
新兴的肾母细胞瘤易感综合征的监测指南更新
Jack J Brzezinski,Kerri D Becktell,Gaëlle Bougeard et al.
Jack J Brzezinski et al.
Wilms tumors are commonly associated with predisposition syndromes. Many of these syndromes are associated with specific phenotypic features and are discussed in the related paper from the AACR Pediatric Cancer Working Group. Guidelines for...
Phase 1 Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies [0.03%]
针对血液系统恶性肿瘤和上皮源性恶性肿瘤ROR1特异性CAR-T细胞Ⅰ期研究
Carla A Jaeger-Ruckstuhl,Jennifer M Specht,Jenna M Voutsinas et al.
Carla A Jaeger-Ruckstuhl et al.
Purpose: The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is expressed in hematopoietic and epithelial cancers but has limited expression on normal adult tissues. This phase 1 study evaluated the safety of targe...